New

Antibody Drug Conjugates Market

2021

Antibody Drug Conjugates Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology (Cleavable Linker, Non-cleavable Linker); Application (Blood Cancer, Brain Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer) and Geography

| Report Code: TIPRE00003494 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Market Insights

Antibody Drug Conjugates Market 2028 By Technology, Application and Geography | The Insight Partners

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!

MARKET OVERVIEW



Antibody Drug Conjugates (ADCs) are designed to deliver cytotoxins to cancer cells, and they can be used to treat solid tumours as well as hematologic cancers. ADCs are kind of biopharmaceutical medications meant for treatment of various type of cancers. ADCs are designed in such a way that they can descriminate between infected cells and normal cells. An ADC can target and bind to cell-surface proteins found on cancer cells, then release its cell-killing drugs with the help of a linker. This characteristic allows ADCs to destroy cancer cells selectively while limiting side effects for patients.

MARKET SCOPE



The "Global Antibody Drug Conjugates Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the antibody drug conjugates market with detailed market segmentation by technology and application. The report provides key statistics on the market status of the leading antibody drug conjugates market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION



  • Based on technology the market is segmented as, cleavable linker and non-cleavable linker.
  • Based on application the market is segmented as, blood cancer, brain cancer, breast cancer, ovarian cancer and lung cancer.

MARKET DYNAMICS


Drivers:



  • Increasing prevalence of cancers such as, solid tumors, haematological disorders are the major driving factors for the market growth.
  • Rising geriatric population across the globe.
  • Presence of strong pipeline of therapeutic agents are also expected to spur the market growth.
  • Extensive R&D efforts for development of novel drug therapies such as ADCs, immunotherapies for management of chronic diseases.

Restraints:



  • However, risk of possibel side effects associated with the treatment are expected to restrain market growth during the forecast period.

REGIONAL FRAMEWORK



The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The antibody drug conjugates market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the antibody drug conjugates market in these regions.

IMPACT OF COVID-19 ON ANTIBODY DRUG CONJUGATES MARKET



COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. There is big shift in demand for antibody drug conjugates and related therapeutics because of pandemic situation and lockdown scenes so that people cannot come out from their homes and can't take their cancer treatments which ultimately affecting the demand for antibody drug conjugates. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

MARKET PLAYERS



The report covers key developments in the antibody drug conjugates market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from antibody drug conjugates market are anticipated to lucrative growth opportunities in the future with the rising demand for antibody drug conjugates in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the antibody drug conjugates market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  • AbbVie Inc.
  • Baxter International Inc
  • Cerbios-Pharma SA
  • F. Hoffmann-La Roche Ltd
  • Lonza
  • Merck KGaA
  • Novasep
  • Pfizer Inc.
  • Piramal Pharma Solutions
  • Syngene International Limited
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Antibody Drug Conjugates Market - By Technology
1.3.2 Antibody Drug Conjugates Market - By Application
1.3.3 Antibody Drug Conjugates Market - By Region
1.3.3.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. ANTIBODY DRUG CONJUGATES MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS

5. ANTIBODY DRUG CONJUGATES MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. ANTIBODY DRUG CONJUGATES MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTIBODY DRUG CONJUGATES - GLOBAL MARKET OVERVIEW
6.2. ANTIBODY DRUG CONJUGATES - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE

7. ANTIBODY DRUG CONJUGATES MARKET - REVENUE AND FORECASTS TO 2028 - TECHNOLOGY
7.1. OVERVIEW
7.2. TECHNOLOGY MARKET FORECASTS AND ANALYSIS
7.3. CLEAVABLE LINKER
7.3.1. Overview
7.3.2. Cleavable Linker Market Forecast and Analysis
7.4. NON-CLEAVABLE LINKER
7.4.1. Overview
7.4.2. Non-cleavable Linker Market Forecast and Analysis
8. ANTIBODY DRUG CONJUGATES MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. BLOOD CANCER
8.3.1. Overview
8.3.2. Blood Cancer Market Forecast and Analysis
8.4. BRAIN CANCER
8.4.1. Overview
8.4.2. Brain Cancer Market Forecast and Analysis
8.5. BREAST CANCER
8.5.1. Overview
8.5.2. Breast Cancer Market Forecast and Analysis
8.6. OVARIAN CANCER
8.6.1. Overview
8.6.2. Ovarian Cancer Market Forecast and Analysis
8.7. LUNG CANCER
8.7.1. Overview
8.7.2. Lung Cancer Market Forecast and Analysis

9. ANTIBODY DRUG CONJUGATES MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Antibody Drug Conjugates Market Overview
9.1.2 North America Antibody Drug Conjugates Market Forecasts and Analysis
9.1.3 North America Antibody Drug Conjugates Market Forecasts and Analysis - By Technology
9.1.4 North America Antibody Drug Conjugates Market Forecasts and Analysis - By Application
9.1.5 North America Antibody Drug Conjugates Market Forecasts and Analysis - By Countries
9.1.5.1 United States Antibody Drug Conjugates Market
9.1.5.1.1 United States Antibody Drug Conjugates Market by Technology
9.1.5.1.2 United States Antibody Drug Conjugates Market by Application
9.1.5.2 Canada Antibody Drug Conjugates Market
9.1.5.2.1 Canada Antibody Drug Conjugates Market by Technology
9.1.5.2.2 Canada Antibody Drug Conjugates Market by Application
9.1.5.3 Mexico Antibody Drug Conjugates Market
9.1.5.3.1 Mexico Antibody Drug Conjugates Market by Technology
9.1.5.3.2 Mexico Antibody Drug Conjugates Market by Application
9.2. EUROPE
9.2.1 Europe Antibody Drug Conjugates Market Overview
9.2.2 Europe Antibody Drug Conjugates Market Forecasts and Analysis
9.2.3 Europe Antibody Drug Conjugates Market Forecasts and Analysis - By Technology
9.2.4 Europe Antibody Drug Conjugates Market Forecasts and Analysis - By Application
9.2.5 Europe Antibody Drug Conjugates Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Antibody Drug Conjugates Market
9.2.5.1.1 Germany Antibody Drug Conjugates Market by Technology
9.2.5.1.2 Germany Antibody Drug Conjugates Market by Application
9.2.5.2 France Antibody Drug Conjugates Market
9.2.5.2.1 France Antibody Drug Conjugates Market by Technology
9.2.5.2.2 France Antibody Drug Conjugates Market by Application
9.2.5.3 Italy Antibody Drug Conjugates Market
9.2.5.3.1 Italy Antibody Drug Conjugates Market by Technology
9.2.5.3.2 Italy Antibody Drug Conjugates Market by Application
9.2.5.4 Spain Antibody Drug Conjugates Market
9.2.5.4.1 Spain Antibody Drug Conjugates Market by Technology
9.2.5.4.2 Spain Antibody Drug Conjugates Market by Application
9.2.5.5 United Kingdom Antibody Drug Conjugates Market
9.2.5.5.1 United Kingdom Antibody Drug Conjugates Market by Technology
9.2.5.5.2 United Kingdom Antibody Drug Conjugates Market by Application
9.2.5.6 Rest of Europe Antibody Drug Conjugates Market
9.2.5.6.1 Rest of Europe Antibody Drug Conjugates Market by Technology
9.2.5.6.2 Rest of Europe Antibody Drug Conjugates Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Antibody Drug Conjugates Market Overview
9.3.2 Asia-Pacific Antibody Drug Conjugates Market Forecasts and Analysis
9.3.3 Asia-Pacific Antibody Drug Conjugates Market Forecasts and Analysis - By Technology
9.3.4 Asia-Pacific Antibody Drug Conjugates Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Antibody Drug Conjugates Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Antibody Drug Conjugates Market
9.3.5.1.1 Australia Antibody Drug Conjugates Market by Technology
9.3.5.1.2 Australia Antibody Drug Conjugates Market by Application
9.3.5.2 China Antibody Drug Conjugates Market
9.3.5.2.1 China Antibody Drug Conjugates Market by Technology
9.3.5.2.2 China Antibody Drug Conjugates Market by Application
9.3.5.3 India Antibody Drug Conjugates Market
9.3.5.3.1 India Antibody Drug Conjugates Market by Technology
9.3.5.3.2 India Antibody Drug Conjugates Market by Application
9.3.5.4 Japan Antibody Drug Conjugates Market
9.3.5.4.1 Japan Antibody Drug Conjugates Market by Technology
9.3.5.4.2 Japan Antibody Drug Conjugates Market by Application
9.3.5.5 South Korea Antibody Drug Conjugates Market
9.3.5.5.1 South Korea Antibody Drug Conjugates Market by Technology
9.3.5.5.2 South Korea Antibody Drug Conjugates Market by Application
9.3.5.6 Rest of Asia-Pacific Antibody Drug Conjugates Market
9.3.5.6.1 Rest of Asia-Pacific Antibody Drug Conjugates Market by Technology
9.3.5.6.2 Rest of Asia-Pacific Antibody Drug Conjugates Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Antibody Drug Conjugates Market Overview
9.4.2 Middle East and Africa Antibody Drug Conjugates Market Forecasts and Analysis
9.4.3 Middle East and Africa Antibody Drug Conjugates Market Forecasts and Analysis - By Technology
9.4.4 Middle East and Africa Antibody Drug Conjugates Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Antibody Drug Conjugates Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Antibody Drug Conjugates Market
9.4.5.1.1 South Africa Antibody Drug Conjugates Market by Technology
9.4.5.1.2 South Africa Antibody Drug Conjugates Market by Application
9.4.5.2 Saudi Arabia Antibody Drug Conjugates Market
9.4.5.2.1 Saudi Arabia Antibody Drug Conjugates Market by Technology
9.4.5.2.2 Saudi Arabia Antibody Drug Conjugates Market by Application
9.4.5.3 U.A.E Antibody Drug Conjugates Market
9.4.5.3.1 U.A.E Antibody Drug Conjugates Market by Technology
9.4.5.3.2 U.A.E Antibody Drug Conjugates Market by Application
9.4.5.4 Rest of Middle East and Africa Antibody Drug Conjugates Market
9.4.5.4.1 Rest of Middle East and Africa Antibody Drug Conjugates Market by Technology
9.4.5.4.2 Rest of Middle East and Africa Antibody Drug Conjugates Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Antibody Drug Conjugates Market Overview
9.5.2 South and Central America Antibody Drug Conjugates Market Forecasts and Analysis
9.5.3 South and Central America Antibody Drug Conjugates Market Forecasts and Analysis - By Technology
9.5.4 South and Central America Antibody Drug Conjugates Market Forecasts and Analysis - By Application
9.5.5 South and Central America Antibody Drug Conjugates Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Antibody Drug Conjugates Market
9.5.5.1.1 Brazil Antibody Drug Conjugates Market by Technology
9.5.5.1.2 Brazil Antibody Drug Conjugates Market by Application
9.5.5.2 Argentina Antibody Drug Conjugates Market
9.5.5.2.1 Argentina Antibody Drug Conjugates Market by Technology
9.5.5.2.2 Argentina Antibody Drug Conjugates Market by Application
9.5.5.3 Rest of South and Central America Antibody Drug Conjugates Market
9.5.5.3.1 Rest of South and Central America Antibody Drug Conjugates Market by Technology
9.5.5.3.2 Rest of South and Central America Antibody Drug Conjugates Market by Application

10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

11. ANTIBODY DRUG CONJUGATES MARKET, KEY COMPANY PROFILES
11.1. ABBVIE INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. BAXTER INTERNATIONAL INC
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. CERBIOS-PHARMA SA
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. F. HOFFMANN-LA ROCHE LTD
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. LONZA
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. MERCK KGAA
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. NOVASEP
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. PFIZER INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. PIRAMAL PHARMA SOLUTIONS
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. SYNGENE INTERNATIONAL LIMITED
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments

12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

- AbbVie Inc.
- Baxter International Inc
- Cerbios-Pharma SA
- F. Hoffmann-La Roche Ltd
- Lonza
- Merck KGaA
- Novasep
- Pfizer Inc.
- Piramal Pharma Solutions
- Syngene International Limited
- Seagen Inc.
- ImmunoGen, Inc
- Genentech USA, Inc
- Antikor
- Oxford BioTherapeutics
TIPRE00003494
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.